JPH0716094A - Production of single-stranded oligonucleotide having promoter sequence of rna polymerase - Google Patents
Production of single-stranded oligonucleotide having promoter sequence of rna polymeraseInfo
- Publication number
- JPH0716094A JPH0716094A JP14360893A JP14360893A JPH0716094A JP H0716094 A JPH0716094 A JP H0716094A JP 14360893 A JP14360893 A JP 14360893A JP 14360893 A JP14360893 A JP 14360893A JP H0716094 A JPH0716094 A JP H0716094A
- Authority
- JP
- Japan
- Prior art keywords
- primer
- sequence
- rna
- nucleic acid
- polymerase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 title claims abstract description 60
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 title claims abstract description 60
- 108091034117 Oligonucleotide Proteins 0.000 title claims abstract description 46
- 238000004519 manufacturing process Methods 0.000 title claims description 11
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 70
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 61
- 238000006243 chemical reaction Methods 0.000 claims abstract description 41
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims abstract description 28
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims abstract description 28
- 230000000694 effects Effects 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims description 40
- 230000000295 complement effect Effects 0.000 claims description 26
- 108020004414 DNA Proteins 0.000 claims description 22
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 21
- 102000053602 DNA Human genes 0.000 claims description 16
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 11
- 108020004682 Single-Stranded DNA Proteins 0.000 claims description 6
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 2
- 108010013845 RNA Polymerase I Proteins 0.000 claims description 2
- 102000017143 RNA Polymerase I Human genes 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 abstract description 9
- 102000039446 nucleic acids Human genes 0.000 description 15
- 108020004707 nucleic acids Proteins 0.000 description 15
- 239000000523 sample Substances 0.000 description 10
- 108091027568 Single-stranded nucleotide Proteins 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 230000003321 amplification Effects 0.000 description 7
- 238000009396 hybridization Methods 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- 230000005026 transcription initiation Effects 0.000 description 7
- 241000607272 Vibrio parahaemolyticus Species 0.000 description 6
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 5
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 5
- 230000004544 DNA amplification Effects 0.000 description 5
- 102100034343 Integrase Human genes 0.000 description 5
- 102000006382 Ribonucleases Human genes 0.000 description 5
- 108010083644 Ribonucleases Proteins 0.000 description 5
- 101710137500 T7 RNA polymerase Proteins 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 101710179002 Hemolytic toxin Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- 108010006464 Hemolysin Proteins Proteins 0.000 description 3
- 239000004677 Nylon Substances 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 3
- RGWHQCVHVJXOKC-SHYZEUOFSA-N dCTP Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO[P@](O)(=O)O[P@](O)(=O)OP(O)(O)=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-N 0.000 description 3
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 3
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 3
- 239000005547 deoxyribonucleotide Substances 0.000 description 3
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 3
- 229920001778 nylon Polymers 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 238000005349 anion exchange Methods 0.000 description 2
- 108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 description 2
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 239000003219 hemolytic agent Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000002463 transducing effect Effects 0.000 description 2
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 2
- 229940045145 uridine Drugs 0.000 description 2
- MXHRCPNRJAMMIM-SHYZEUOFSA-N 2'-deoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 description 1
- NVWKYNBWYYJZTK-UHFFFAOYSA-N 8-(2,5-dioxopyrrolidin-1-yl)oxy-8-oxooctanoic acid Chemical compound OC(=O)CCCCCCC(=O)ON1C(=O)CCC1=O NVWKYNBWYYJZTK-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000193385 Geobacillus stearothermophilus Species 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010065868 RNA polymerase SP6 Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 241000205180 Thermococcus litoralis Species 0.000 description 1
- 241000589500 Thermus aquaticus Species 0.000 description 1
- 241000589499 Thermus thermophilus Species 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 108010068991 arginyl-threonyl-prolyl-prolyl-prolyl-seryl-glycine Proteins 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- MXHRCPNRJAMMIM-UHFFFAOYSA-N desoxyuridine Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-UHFFFAOYSA-N 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000037230 mobility Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 239000001047 purple dye Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- ADWNFGORSPBALY-UHFFFAOYSA-M sodium;2-[dodecyl(methyl)amino]acetate Chemical compound [Na+].CCCCCCCCCCCCN(C)CC([O-])=O ADWNFGORSPBALY-UHFFFAOYSA-M 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明はRNAポリメラーゼのプ
ロモーター配列をもつ1本鎖オリゴヌクレオチドの製造
法に関し、また該RNAポリメラーゼのプロモーター配
列をもつ一本鎖オリゴヌクレオチドを使用する特定核酸
配列の増幅法に関する。TECHNICAL FIELD The present invention relates to a method for producing a single-stranded oligonucleotide having an RNA polymerase promoter sequence, and a method for amplifying a specific nucleic acid sequence using a single-stranded oligonucleotide having the RNA polymerase promoter sequence. Regarding
【0002】[0002]
【従来の技術】ハイブリダイゼーションによる核酸の検
出は、遺伝病、癌、感染症などの診断における有効な手
段として汎用されるようになってきた。しかしながら、
特定核酸配列が非常に僅少な場合には、感度上の問題等
によりその検出が困難である。そのため、特定核酸配列
の増幅法の開発が試みられてきた。その最初の試みとし
て、目的とする核酸をDNAポリメラーゼにより増幅さ
せる方法(特開昭61-274697号公報、以下PCR 法と略
す)が開発された。しかしながら、PCR 法は、その原理
上、特殊な温度制御装置を必要とし、増幅効率も2倍づ
つしか増幅できないという欠点を有している。またDN
Aリガーゼを用いる増幅法(WO89/12696、特開平2-2934
号公報など、以下LCR 法と略す)も考案されたがPCR 法
と同様、特殊な温度制御装置と必要とする。2. Description of the Related Art Nucleic acid detection by hybridization has come to be widely used as an effective means in diagnosis of genetic diseases, cancers, infectious diseases and the like. However,
If the specific nucleic acid sequence is very small, it is difficult to detect it due to problems such as sensitivity. Therefore, attempts have been made to develop a method for amplifying a specific nucleic acid sequence. As the first attempt, a method for amplifying a target nucleic acid with a DNA polymerase (JP-A-61-274697, hereinafter abbreviated as PCR method) was developed. However, the PCR method has a drawback that it requires a special temperature control device in principle, and that the amplification efficiency can be amplified only twice. Also DN
Amplification method using A ligase (WO89 / 12696, JP-A-2-2934
The following abbreviations such as the LCR method) were also devised, but similar to the PCR method, they require a special temperature control device.
【0003】そこで、特殊な温度制御装置を必要とせ
ず、効率よく遺伝子を増幅する方法が必要とされ、RN
Aポリメラーゼを用いた遺伝子増幅方法(特開平2-5864
号公報、特開平4-501057号公報など、以下NASBA法と略
す)が開発された。NASBA法は、転写開始配列を有する
プライマーと特定核酸配列をアニールさせ、DNAポリ
メラーゼで伸長反応後、熱をかけてRNAポリメラーゼ
のプロモーター配列をもつ一本鎖オリゴヌクレオチドを
得る。その後、RNAポリメラーゼのプロモーター配列
(転写開始配列)の性質を利用し、一定温度で遺伝子増
幅反応を行うものである。また、NASBA法はメッセンジ
ャーRNAからの遺伝子増幅が可能である。この方法
は、転写開始配列を有するプライマーを特定伝達RNA
に結合し、RNA依存性DNAポリメラーゼ(逆転写酵
素)で相補的DNAを合成後、リボヌクレアーゼ(RNase
H)処理で伝達RNAを分解し、RNAポリメラーゼのプ
ロモーター配列をもつ一本鎖オリゴヌクレオチドを得
る。その後、転写開始配列の性質を利用し一定温度で遺
伝子増幅反応を行うものである。Therefore, there is a need for a method for efficiently amplifying genes without the need for a special temperature control device.
Gene amplification method using A polymerase (JP-A-2-5864)
The following is abbreviated as "NASBA method", such as Japanese Patent Laid-Open Publication No. 4-501057. In the NASBA method, a primer having a transcription initiation sequence and a specific nucleic acid sequence are annealed, an extension reaction is performed with DNA polymerase, and then heat is applied to obtain a single-stranded oligonucleotide having a promoter sequence of RNA polymerase. After that, the gene amplification reaction is performed at a constant temperature by utilizing the property of the promoter sequence (transcription initiation sequence) of RNA polymerase. In addition, the NASBA method enables gene amplification from messenger RNA. In this method, a primer having a transcription initiation sequence is used to specify a transfer RNA.
To RNA and synthesize complementary DNA with RNA-dependent DNA polymerase (reverse transcriptase).
H) treatment decomposes the transcribed RNA to obtain a single-stranded oligonucleotide having a promoter sequence of RNA polymerase. After that, the gene amplification reaction is performed at a constant temperature by utilizing the property of the transcription initiation sequence.
【0004】[0004]
【発明が解決しようとする課題】上記のように、PCR法
は特殊な温度制御装置と高価な耐熱性DNAポリメラー
ゼを必要とし、増幅効率も2倍づつしか増幅できないと
いう欠点を有している。この欠点を解決すべくNASBA法
が開発された。しかしながら、このNASBA法も反応の中
間工程であるRNAポリメラーゼのプロモーター配列を
もつ一本鎖オリゴヌクレオチドを得る工程において、加
熱処理(95℃で5分間処理後、冷却)を行わざるを得ず
操作が煩雑となる。また、NASBA法は伝達RNAからの
遺伝子増幅が可能であり、RNAリボヌクレアーゼの使
用により煩雑な加熱処理を省略できるが、伝達RNAか
らの増幅法にのみ適用し、DNAからの増幅には適さな
い。As described above, the PCR method has a drawback that it requires a special temperature control device and an expensive thermostable DNA polymerase, and the amplification efficiency can be amplified only twice. The NASBA method was developed to solve this drawback. However, in this NASBA method, in the step of obtaining a single-stranded oligonucleotide having a promoter sequence of RNA polymerase, which is an intermediate step of the reaction, heat treatment (treatment at 95 ° C. for 5 minutes followed by cooling) is unavoidable. It becomes complicated. Further, the NASBA method allows gene amplification from transducing RNA, and the complicated heat treatment can be omitted by using RNA ribonuclease, but is applied only to the amplifying method from transducing RNA and is not suitable for amplification from DNA.
【0005】本発明の目的は、上記のような従来からの
問題点を解決するものであり、その目的とするところ
は、RNAポリメラーゼのプロモーター配列をもつ一本
鎖オリゴヌクレオチドを得る工程において煩雑な加熱処
理を必要としない簡便な製造法を提供することにある。The object of the present invention is to solve the above-mentioned conventional problems, and the object thereof is to complicate the step of obtaining a single-stranded oligonucleotide having a promoter sequence of RNA polymerase. It is to provide a simple manufacturing method that does not require heat treatment.
【0006】[0006]
【課題を解決するための手段】本発明者らはこれらの課
題を解決すべく鋭意研究をすすめた結果、本発明に到達
した。すなわち本発明は次の工程を含むことを特徴とす
るRNAポリメラーゼのプロモーター配列をもつ1本鎖
オリゴヌクレオチドを製造する方法である。 (a)特定核酸配列に、剥離用プライマーおよびRNA
ポリメラーゼのプロモーター配列をもつ第1プライマー
をハイブリダイズさせる。(ここで剥離用プライマーお
よびRNAポリメラーゼのプロモーター配列をもつ第1
プライマーは特定核酸配列の各相補的配列に結合でき、
その位置関係は剥離用プライマーの特定核酸配列の相補
的配列がRNAポリメラーゼのプロモーター配列をもつ
第1プライマーの特定核酸配列の相補的配列の3’側に
存在する。) (b)次いでヘリカーゼ様活性を有するDNAポリメラ
ーゼを用いて、RNAポリメラーゼのプロモーター配列
をもつ第1プライマーからの伸長反応を行う。 (c)さらに剥離用プライマーからの伸長反応に伴い、
特定核酸配列からRNAポリメラーゼのプロモーター配
列をもつ第1プライマーと該第1プライマーからの伸長
物で形成されるRNAポリメラーゼのプロモーター配列
をもつ1本鎖オリゴヌクレオチドを分離する。The present inventors have arrived at the present invention as a result of intensive studies to solve these problems. That is, the present invention is a method for producing a single-stranded oligonucleotide having a promoter sequence of RNA polymerase, which comprises the following steps. (A) A primer for peeling and RNA for a specific nucleic acid sequence
A first primer having a polymerase promoter sequence is hybridized. (Here, a first primer having a peeling primer and a promoter sequence of RNA polymerase
A primer can bind to each complementary sequence of a particular nucleic acid sequence,
The positional relationship is such that the complementary sequence of the specific nucleic acid sequence of the peeling primer is present 3'to the complementary sequence of the specific nucleic acid sequence of the first primer having the promoter sequence of RNA polymerase. (B) Then, using a DNA polymerase having helicase-like activity, an extension reaction from the first primer having a promoter sequence of RNA polymerase is performed. (C) Furthermore, with the extension reaction from the peeling primer,
A single-stranded oligonucleotide having an RNA polymerase promoter sequence formed by a first primer having an RNA polymerase promoter sequence and an extension product from the first primer is separated from the specific nucleic acid sequence.
【0007】本発明では工程(b)および工程(c)が
同時に行われることが好ましい。また本発明のRNAポ
リメラーゼのプロモーター配列をもつ1本鎖オリゴヌク
レオチドを製造する方法では、工程(c)において形成
されるRNAポリメラーゼのプロモーター配列をもつ1
本鎖オリゴヌクレオチドと特定核酸配列との二重鎖領域
が、ヘリカーゼ様活性をもつDNAポリメラーゼの作用
により、剥離用プライマーからの伸長反応にともない巻
戻され、RNAポリメラーゼのプロモーター配列をもつ
1本鎖オリゴヌクレオチドが特定核酸配列から分離され
ることが好ましい。In the present invention, it is preferable that step (b) and step (c) are carried out simultaneously. Further, in the method for producing a single-stranded oligonucleotide having a promoter sequence of RNA polymerase of the present invention, 1 having a promoter sequence of RNA polymerase formed in step (c) is used.
The double-stranded region of the double-stranded oligonucleotide and the specific nucleic acid sequence is unwound by the action of the DNA polymerase having helicase-like activity in association with the extension reaction from the primer for peeling, and the single-stranded region having the promoter sequence of RNA polymerase It is preferred that the oligonucleotide is separated from the specific nucleic acid sequence.
【0008】また本発明は次の工程を含むことを特徴と
するRNAポリメラーゼのプロモーター配列をもつ1本
鎖オリゴヌクレオチドを用いた特定核酸配列の増幅法で
ある。 (A)上記工程(a)〜工程(c)を経て得られたRN
Aポリメラーゼのプロモーター配列をもつ1本鎖オリゴ
ヌクレオチドに第2プライマーをハイブリダイズさせ
る。 (B)次いでDNAポリメラーゼを用いて伸長反応を行
い、二重鎖DNAを合成した後、 (C)二重鎖DNAにRNAポリメラーゼを反応させて
一重鎖RNAを複数合成する。 (D)一重鎖RNAを鋳型として、第2プライマーをハ
イブリダイズさせる。 (E)次いでRNA依存性DNAポリメラーゼを用い
て、RNA−DNAハイブリッドを形成させる。 (F)RNA−DNAハイブリッドのRNA部分を分解
し、一本鎖DNAを得る。 (G)得られた一本鎖DNAにRNAポリメラーゼのプ
ロモーター配列をもつ第1プライマーをハイブリダイズ
させ、伸長反応を行い、二重鎖DNAを合成する。 (H)さらに工程(C)から(G)を繰り返して特定核
酸配列を増幅する。The present invention is also a method for amplifying a specific nucleic acid sequence using a single-stranded oligonucleotide having an RNA polymerase promoter sequence, which comprises the following steps. (A) RN obtained through the above steps (a) to (c)
A second primer is hybridized with a single-stranded oligonucleotide having a promoter sequence of A polymerase. (B) Next, an extension reaction is performed using a DNA polymerase to synthesize double-stranded DNA, and then (C) the double-stranded DNA is reacted with RNA polymerase to synthesize a plurality of single-stranded RNAs. (D) The second primer is hybridized with the single-stranded RNA as a template. (E) Next, an RNA-DNA hybrid is formed using an RNA-dependent DNA polymerase. (F) The RNA portion of the RNA-DNA hybrid is decomposed to obtain single-stranded DNA. (G) The obtained single-stranded DNA is hybridized with a first primer having an RNA polymerase promoter sequence, and an extension reaction is performed to synthesize a double-stranded DNA. (H) Further, steps (C) to (G) are repeated to amplify the specific nucleic acid sequence.
【0009】以下に本発明に使用される用語を説明す
る。「伸長反応」とは核酸配列に十分に相補的な配列を
もつプライマーを核酸配列にハイブリダイズした後、D
NAポリメラーゼとデオキシアデノシン5'−三リン酸
(dATP)、デオキシシチジン5'−三リン酸(dCTP)、デ
オキシグアノシン5'−三リン酸(dGTP)、及びデオキシ
チミジン5'−三リン酸(dTTP)の存在下、プライマーに
デオキシヌクレオチドを共有結合し、核酸配列に相補的
なDNA配列を順次合成する反応である。「剥離用プラ
イマー」とはRNAポリメラーゼのプロモーター配列を
もつ一本鎖オリゴヌクレオチドを特定核酸配列から分離
させるためのプライマーである。剥離用プライマーから
の伸長反応に伴い、伸長反応方向の上流に存在するRN
Aポリメラーゼのプロモーター配列をもつ一本鎖オリゴ
ヌクレオチドがヘリカーゼ様活性をもつDNAポリメラ
ーゼの作用により特定核酸配列から分離される。The terms used in the present invention are explained below. “Extension reaction” means that after a primer having a sequence sufficiently complementary to a nucleic acid sequence is hybridized with the nucleic acid sequence, D
NA polymerase and deoxyadenosine 5'-triphosphate (dATP), deoxycytidine 5'-triphosphate (dCTP), deoxyguanosine 5'-triphosphate (dGTP), and deoxythymidine 5'-triphosphate (dTTP) In the presence of a), a deoxynucleotide is covalently bound to the primer to sequentially synthesize a DNA sequence complementary to the nucleic acid sequence. The "peeling primer" is a primer for separating a single-stranded oligonucleotide having an RNA polymerase promoter sequence from a specific nucleic acid sequence. RN existing upstream of the extension reaction direction with the extension reaction from the stripping primer
A single-stranded oligonucleotide having a promoter sequence for A polymerase is separated from a specific nucleic acid sequence by the action of a DNA polymerase having helicase-like activity.
【0010】「RNAポリメラーゼのプロモーター配
列」とはRNAポリメラーゼが特異的に結合する配列で
ある。RNAポリメラーゼはこのプロモーター配列に特
異的に結合し、該プロモーター配列よりも下流のDNA
配列と相同なRNAを合成する。「RNAポリメラーゼ
のプロモーター配列をもつ第1プライマー」とは5’末
端にT3RNAポリメラーゼ、T7RNAポリメラー
ゼ、SP6RNAポリメラーゼなどのプロモーター配列
を有し、3’末端側に特定核酸配列に相補的な核酸配列
を有するプライマーである。「RNAポリメラーゼのプ
ロモーター配列をもつ一本鎖オリゴヌクレオチド」とは
RNAポリメラーゼのプロモーター配列をもつ第1プラ
イマーとDNAポリメラーゼによる該第1プライマーか
らの伸長物の結合物である。The "RNA polymerase promoter sequence" is a sequence to which RNA polymerase specifically binds. RNA polymerase specifically binds to this promoter sequence and DNA downstream of the promoter sequence.
Synthesize RNA homologous to the sequence. The “first primer having a promoter sequence of RNA polymerase” has a promoter sequence such as T3RNA polymerase, T7RNA polymerase, SP6RNA polymerase at the 5 ′ end and a nucleic acid sequence complementary to a specific nucleic acid sequence at the 3 ′ end side. It is a primer. The "single-stranded oligonucleotide having a promoter sequence of RNA polymerase" is a combination product of a first primer having a promoter sequence of RNA polymerase and an extension product from the first primer by DNA polymerase.
【0011】「ヘリカーゼ様活性をもつDNAポリメラ
ーゼ」とはプライマーからの伸長反応を行いDNAを合
成しつつ、伸長方向に存在する二本鎖DNA部位を巻き
戻して一本鎖DNAに変換するポリメラーゼのことであ
る。例えば、PHI29DNAポリメラーゼ、クレノウフラ
グメント(Klenow fragment)、M2DNAポリメラー
ゼなどがヘリカーゼ様活性を有しており、本発明に使用
可能である。また耐熱性DNAポリメラーゼであるTt
h(Thermus thermophilus)DNAポリメラーゼ、Ta
q(Thermus aquaticus)DNAポリメラーゼ、Ven
t(Thermococcuslitoralis)DNAポリメラーゼ、B
st(Bacillus stearothermophilus)DNAポリメラ
ーゼなどもヘリカーゼ様活性を有しており本発明に使用
できる。The "DNA polymerase having helicase-like activity" is a polymerase that synthesizes DNA by performing an extension reaction from a primer and unwinds a double-stranded DNA site existing in the extension direction to convert it into a single-stranded DNA. That is. For example, PHI29 DNA polymerase, Klenow fragment, M2 DNA polymerase and the like have helicase-like activity and can be used in the present invention. In addition, Tt which is a thermostable DNA polymerase
h (Thermus thermophilus) DNA polymerase, Ta
q (Thermus aquaticus) DNA polymerase, Ven
t (Thermococcus litoralis) DNA polymerase, B
st (Bacillus stearothermophilus) DNA polymerase and the like also have helicase-like activity and can be used in the present invention.
【0012】本発明に使用する特定核酸配列は一重鎖D
NAであっても二重鎖DNAであってもよい。それらが
人為的に作成されたものであっても、天然に存在するも
のであっても支障はない。天然のDNAを使用する場合
には常法に従い検体から抽出後、本発明に利用できる。
検体の具体的な調製法としては、例えば腸炎ビブリオの
菌株をブレインハートインフュージョン培地に接種し
て、一晩培養する。成育したコロニーをエッペンドルフ
チューブにかきとり、希釈用緩衝液に懸濁し、さらにこ
こへ、プロテイナーゼ、溶菌液を加えて撹拌し、約60℃
で30分間インキュベートし、次いで得られた溶解液を、
フェノール、クロロホルムなどで抽出後、エタノール沈
澱して核酸を得る。The specific nucleic acid sequence used in the present invention is a single-stranded chain D
It may be NA or double-stranded DNA. It does not matter whether they are artificially created or naturally occurring. When natural DNA is used, it can be used in the present invention after being extracted from a sample according to a conventional method.
As a specific method for preparing a sample, for example, a strain of Vibrio parahaemolyticus is inoculated into a brain heart infusion medium and cultured overnight. Scrap the grown colonies in an Eppendorf tube, suspend in a diluting buffer, add proteinase and lysate to this, and stir at about 60 ° C.
Incubate for 30 minutes at
After extraction with phenol, chloroform, etc., ethanol precipitation is performed to obtain a nucleic acid.
【0013】本発明においてRNAポリメラーゼのプロ
モーター配列を持つ第1プライマーのプロモーター配列
は、T3RNAポリメラーゼ、T7RNAポリメラーゼ、SP
6 RNAポリメラーゼ用のプロモーター配列などを用い
ればよい。該第1プライマーと特定核酸配列とのアニー
ル部位の配列長に特に制限はなく、好ましくは10〜100b
p 、特に好ましくは10〜50bp、更に好ましくは15〜30bp
がよいが、これに限定されるものではない。プライマー
の調製法は従来公知の方法に従う。具体的な手法として
は、例えばABI社マニュアルに従ってホスホアミダイ
ド法により製造する。各種オリゴヌクレオチドの脱保護
はアンモニア水で実施する。精製はFPLCで逆相カラ
ムにて実施してもよい。In the present invention, the promoter sequence of the first primer having the promoter sequence of RNA polymerase is T3 RNA polymerase, T7 RNA polymerase, SP
6 A promoter sequence for RNA polymerase or the like may be used. The sequence length of the annealing site between the first primer and the specific nucleic acid sequence is not particularly limited, and is preferably 10 to 100b.
p, particularly preferably 10 to 50 bp, further preferably 15 to 30 bp
However, the present invention is not limited to this. The method for preparing the primer follows a conventionally known method. As a specific method, for example, it is produced by the phosphoramidide method according to the manual of ABI company. Deprotection of various oligonucleotides is performed with aqueous ammonia. Purification may be performed by FPLC on a reverse phase column.
【0014】本発明では、剥離用プライマーおよびRN
Aポリメラーゼのプロモーター配列をもつ第1プライマ
ーは特定核酸配列の各相補的配列に結合でき、その位置
関係は剥離用プライマーの特定核酸配列の相補的配列が
RNAポリメラーゼのプロモーター配列をもつ第1プラ
イマーの特定核酸配列の相補的配列の3’側に存在す
る。剥離用プライマーを設計する場合、剥離用プライマ
ーと特定核酸配列とのアニール部位の配列長に特に制限
はなく、好ましくは10〜100bp 、特に好ましくは10〜50
bp、更に好ましくは15〜30bpがよいが、これに限定され
るものではない。In the present invention, the stripping primer and RN are used.
The first primer having the promoter sequence of A polymerase can bind to each complementary sequence of the specific nucleic acid sequence, and its positional relationship is such that the complementary sequence of the specific nucleic acid sequence of the peeling primer has the RNA polymerase promoter sequence. It is located 3'to the complementary sequence of the specific nucleic acid sequence. When designing the stripping primer, the sequence length of the annealing site between the stripping primer and the specific nucleic acid sequence is not particularly limited, preferably 10 to 100 bp, particularly preferably 10 to 50 bp.
bp, more preferably 15 to 30 bp, but not limited thereto.
【0015】以下に本発明を図面(図1および図2)を
用いて説明する。剥離用プライマーaとRNAポリメラ
ーゼのプロモーター配列をもつ第1プライマーbは特定
核酸配列の相補的結合配列に結合でき、その位置関係は
該剥離用プライマーaの特定核酸配列の相補的結合配列
a’が該第1プライマーbの特定核酸配列の相補的結合
配列b’の3’側に存在しなければならない。該第1プ
ライマーbと剥離用プライマーaの特定核酸配列の相補
的結合配列間の距離(b’とa’間の距離)に特に制限
はなく、ヘリカーゼ様活性をもつDNAポリメラーゼに
より該剥離用プライマーaからの伸長反応にともない、
該第1プライマーbと該第1プライマーbからの伸長物
cが特定核酸配列から分離する距離に設定すればよい。
好ましくは0〜2000bp、特に好ましくは20〜1000bpがよ
いが、これに限定されるものではない。The present invention will be described below with reference to the drawings (FIGS. 1 and 2). The stripping primer a and the first primer b having the promoter sequence of RNA polymerase can bind to the complementary binding sequence of the specific nucleic acid sequence, and the positional relationship is such that the complementary binding sequence a ′ of the specific nucleic acid sequence of the stripping primer a is It must be present 3'to the complementary binding sequence b'of the specific nucleic acid sequence of the first primer b. The distance between the complementary binding sequences of the specific nucleic acid sequences of the first primer b and the stripping primer a (distance between b ′ and a ′) is not particularly limited, and the stripping primer can be formed by a DNA polymerase having helicase-like activity. With the extension reaction from a,
The distance may be set such that the first primer b and the extension product c from the first primer b are separated from the specific nucleic acid sequence.
It is preferably 0 to 2000 bp, particularly preferably 20 to 1000 bp, but is not limited thereto.
【0016】剥離用プライマーaとRNAポリメラーゼ
のプロモーター配列を持つ第1プライマーbは以下の方
法に基づき特定核酸配列とアニールさせる(工程a)。
特定核酸配列が二本鎖DNAの場合には、該特定核酸配
列と該第1プライマーbと剥離用プライマーaを混合
し、80〜105 ℃で2〜5分間加熱後、室温になるまで放
置する。特定核酸配列が一本鎖DNAの場合には、該特
定核酸配列と該第1プライマーbと剥離用プライマーa
を混合し、しばらく放置してもよいし、50〜105 ℃で2
〜5分間加熱後、室温になるまで放置してもよい。アニ
ール反応終了後、dNTP(dATP、dCTP、dGTP、dTTPの4種
のデオキシリボヌクレオチド)存在下、ヘリカーゼ様活
性をもつDNAポリメラーゼを用いて、剥離用プライマ
ーaとRNAポリメラーゼのプロモーター配列をもつ第
1プライマーbからの伸長反応を生じせしめる(工程
b)。該第1プライマーbと第1プライマーbからの伸
長物cは、剥離用プライマーaからの伸長反応に従っ
て、特定核酸配列と形成される二重鎖領域が、ヘリカー
ゼ様活性をもつDNAポリメラーゼの作用により巻戻さ
れ、RNAポリメラーゼのプロモーター配列をもつ一本
鎖オリゴヌクレオチドdが特定核酸配列から分離される
(工程c)。剥離用プライマーaからの伸長反応とRN
Aポリメラーゼのプロモーター配列を持つ第1プライマ
ーbからの伸長反応(工程b)と、RNAポリメラーゼ
のプロモーター配列を持つ一本鎖オリゴヌクレオチドd
が特定核酸配列から分離される反応(工程c)を同時に
生じせしめても何等問題はない。The stripping primer a and the first primer b having an RNA polymerase promoter sequence are annealed to the specific nucleic acid sequence according to the following method (step a).
When the specific nucleic acid sequence is double-stranded DNA, the specific nucleic acid sequence, the first primer b and the stripping primer a are mixed, heated at 80 to 105 ° C. for 2 to 5 minutes, and then allowed to stand at room temperature. . When the specific nucleic acid sequence is single-stranded DNA, the specific nucleic acid sequence, the first primer b, and the stripping primer a
You may mix and leave for a while, or 2 at 50 ~ 105 ℃
After heating for ~ 5 minutes, it may be left to stand until it reaches room temperature. After completion of the annealing reaction, a DNA polymerase having helicase-like activity was used in the presence of dNTP (4 types of deoxyribonucleotides of dATP, dCTP, dGTP, and dTTP) to remove the primer a and a first primer having a promoter sequence of RNA polymerase. The extension reaction from b is caused (step b). The first primer b and the extension product c from the first primer b are produced by the action of a DNA polymerase having a helicase-like activity in the double-stranded region formed with a specific nucleic acid sequence according to the extension reaction from the stripping primer a. When unwound, the single-stranded oligonucleotide d having the promoter sequence of RNA polymerase is separated from the specific nucleic acid sequence (step c). Extension reaction from stripping primer a and RN
Extension reaction from the first primer b having the A polymerase promoter sequence (step b), and single-stranded oligonucleotide d having the RNA polymerase promoter sequence
There is no problem even if the reaction (step c) in which is separated from the specific nucleic acid sequence occurs at the same time.
【0017】RNAポリメラーゼのプロモーター配列を
もつ一本鎖オリゴヌクレオチドの具体的な製法の一例と
しては、腸炎ビブリオのゲノムを緩衝液に懸濁し、デオ
キシリボヌクレオチドおよびT7転写開始配列と耐熱性溶
血毒遺伝子に相同な配列を有するプライマー1および耐
熱性溶血毒遺伝子の配列に相同な配列を有する剥離プラ
イマー2を混合し、約95℃に加熱後、室温になるまで放
置する。DNAポリメラーゼを添加し、約30℃で保温し
反応を行う。As an example of a specific method for producing a single-stranded oligonucleotide having a promoter sequence of RNA polymerase, the genome of Vibrio parahaemolyticus is suspended in a buffer solution to obtain a deoxyribonucleotide, a T7 transcription initiation sequence, and a heat-resistant hemolysin gene. Primer 1 having a homologous sequence and peeling primer 2 having a sequence homologous to the thermostable hemolysin gene sequence are mixed, heated to about 95 ° C., and then allowed to stand until room temperature. Add DNA polymerase and incubate at about 30 ° C to carry out reaction.
【0018】本発明の製造法により製造されたRNAポ
リメラーゼのプロモーター配列をもつ1本鎖オリゴヌレ
オチドdを使用して核酸の増幅を行うには、まず該一本
鎖ヌクレオチドdに相補的な第2プライマーeをアニー
ルさせ(図2、工程A)、DNAポリメラーゼ反応によ
り二重鎖DNAを形成させる(工程B)。該二本鎖DN
AにRNAポリメラーゼを反応させ、一重鎖RNAfを
合成させる(工程C)。該一重鎖RNAには上記一本鎖
ヌクレオチドに相補的な第2プライマーeがアニール可
能であり(工程D)、RNA依存性DNAポリメラーゼ
(逆転写酵素)により該一重鎖RNAfに相補的なDN
A配列gを合成する(工程E)。一重鎖RNAに相補的
なDNA配列gと一重鎖RNAfを例えばリボヌクレア
ーゼを用いて分離し(工程F)、該一重鎖RNAに相補
的なDNA配列gとRNAポリメラーゼのプロモーター
配列をもつ第一プライマーbをアニールさせ、DNAポ
リメラーゼにより二重鎖にする(工程G)。以上の反応
を少なくとも1回繰り返し、増幅反応を行う。In order to amplify a nucleic acid using a single-stranded oligonucleotide d having a promoter sequence of RNA polymerase produced by the production method of the present invention, first, a second primer complementary to the single-stranded nucleotide d is used. e is annealed (FIG. 2, step A), and double-stranded DNA is formed by a DNA polymerase reaction (step B). The double-stranded DN
A is reacted with RNA polymerase to synthesize single-stranded RNAf (step C). A second primer e complementary to the single-stranded nucleotide can be annealed to the single-stranded RNA (step D), and DN complementary to the single-stranded RNAf can be formed by RNA-dependent DNA polymerase (reverse transcriptase).
A sequence g is synthesized (step E). The DNA sequence g complementary to the single-stranded RNA and the single-stranded RNAf are separated using, for example, ribonuclease (step F), and the first primer b having the DNA sequence g complementary to the single-stranded RNA and the promoter sequence of RNA polymerase Are annealed and double-stranded with DNA polymerase (step G). The above reaction is repeated at least once to carry out the amplification reaction.
【0019】本発明に使用する第2プライマーとはRN
Aポリメラーゼのプロモーター配列をもつ一本鎖ヌクレ
オチドに相補的なプライマーをいう。The second primer used in the present invention is RN
A primer complementary to a single-stranded nucleotide having a promoter sequence of A polymerase.
【0020】本発明において特定核酸配列の検出を行う
には、上記増幅法により増幅した試料を電気泳動、サザ
ンブロット、ドットブロットなどを行う必要があり、具
体的な検出法の一例としては、上記工程aから工程cに
より得られた反応液にRNAポリメラーゼのプロモータ
ー配列をもつ一本鎖ヌクレオチドに相補的な第2プライ
マー、RNA依存性DNAポリメラーゼ(逆転写酵
素)、RNAポリメラーゼおよび必要によりリボヌクレ
アーゼを添加して約42℃で反応させ、反応液を例えばナ
イロン膜に数μl滴下後、放射線標識プローブまたは酵
素標識プローブをハイブリダイズさせて検出できる。ま
た別な検出例としては、上記第2プライマー、DTT、
RNA依存性DNAポリメラーゼ(例、AMV逆転写酵
素)、RNAポリメラーゼ(例、T7RNAポリメラー
ゼ)および必要によりリボヌクレアーゼ(例、RNaseH)
を添加して約42℃で反応させ、反応液をアガロースゲル
電気泳動し、エチジウムブロマイド染色した後、紫外線
での蛍光を検出する。反応液の他に分子量マーカーも同
時に泳動し、相対泳動度の比較により、検出されたヌク
レオチド断片の長さを算出することができる。In the present invention, in order to detect a specific nucleic acid sequence, it is necessary to subject the sample amplified by the above-mentioned amplification method to electrophoresis, Southern blotting, dot blotting, etc. As one example of a concrete detecting method, A second primer complementary to a single-stranded nucleotide having an RNA polymerase promoter sequence, an RNA-dependent DNA polymerase (reverse transcriptase), an RNA polymerase, and optionally a ribonuclease are added to the reaction solution obtained in the steps a to c. Then, the reaction is carried out at about 42 ° C., and several μl of the reaction solution is dropped on, for example, a nylon membrane, and then it can be detected by hybridizing with a radiolabeled probe or an enzyme labeled probe. As another detection example, the second primer, DTT,
RNA-dependent DNA polymerase (eg AMV reverse transcriptase), RNA polymerase (eg T7 RNA polymerase) and optionally ribonuclease (eg RNaseH)
Is added and reacted at about 42 ° C., the reaction solution is subjected to agarose gel electrophoresis and stained with ethidium bromide, and then fluorescence from ultraviolet rays is detected. In addition to the reaction solution, a molecular weight marker is also electrophoresed at the same time, and the length of the detected nucleotide fragment can be calculated by comparing the relative mobilities.
【0021】[0021]
【発明の効果】従来方法では、RNAポリメラーゼのプ
ロモーター配列をもつ1本鎖オリゴヌレオチドを得るた
めに加熱処理(95℃で5分間処理後、冷却)を必要と
し、この加熱操作は反応を自動化する際の障壁となり、
装置自体に加熱装置を設けなければならない。ところ
が、本発明ではヘリカーゼ様活性をもつDNAポリメラ
ーゼを使用して、その操作を簡便化できることにより、
このような煩雑な操作および装置を必要とせずに、RN
Aポリメラーゼのプロモーター配列をもつ1本鎖オリゴ
ヌレオチドを得ることができる。本発明の1本鎖オリゴ
ヌレオチドの製造法は、塩基配列が既知の核酸をその初
期に存在する量に比較してより大量に生成させる増幅方
法に適用できる。また特定核酸配列の検出法にも適用で
きる。INDUSTRIAL APPLICABILITY In the conventional method, heat treatment (treatment at 95 ° C. for 5 minutes, followed by cooling) is required to obtain a single-stranded oligonucleotide having a promoter sequence of RNA polymerase, and this heating operation is used for automating the reaction. Barrier to
A heating device must be provided on the device itself. However, in the present invention, a DNA polymerase having helicase-like activity is used, and its operation can be simplified,
RN without the need for such complicated operations and devices
A single-stranded oligonucleotide having a promoter sequence for A polymerase can be obtained. The method for producing a single-stranded oligonucleotide of the present invention can be applied to an amplification method in which a nucleic acid having a known base sequence is produced in a larger amount as compared with the amount present in the initial stage. It can also be applied to a method for detecting a specific nucleic acid sequence.
【0022】[0022]
【実施例】次に実施例を用いて本発明を具体的に説明す
る。 実施例1 (各種オリゴヌクレオチドの合成)ABI社DNAシン
セサイザー391型を用いて、ホスホアミダイト法にて
配列表に示される配列、すなわち、T7RNAポリメラー
ゼのプロモーター配列(T7転写開始配列)および耐熱性
溶血毒遺伝子に相同な配列を有する第1プライマー(配
列番号1)、耐熱性溶血毒遺伝子の配列に相同な配列を
有する剥離用プライマー(配列番号2)、RNAポリメ
ラーゼのプロモーター配列をもつ一本鎖オリゴヌクレオ
チドに相補的な第2プライマー(耐熱性溶血毒遺伝子の
配列に相補的な配列を有する)(配列番号3)を合成し
た。具体的な手法はABI社マニュアルに従い、0.2Mス
ケールで実施した。各種オリゴヌクレオチドの脱保護は
アンモニア水で55℃一夜実施した。精製はファルマシア
社製FPLCで逆相カラムにて実施した。EXAMPLES The present invention will be described in detail with reference to examples. Example 1 (Synthesis of various oligonucleotides) Using a DNA synthesizer type 391 manufactured by ABI, a sequence shown in the sequence listing by the phosphoamidite method, that is, a promoter sequence of T7 RNA polymerase (T7 transcription initiation sequence) and a heat-resistant hemolytic poison A first primer having a sequence homologous to the gene (SEQ ID NO: 1), a stripping primer having a sequence homologous to the thermostable hemolysin gene (SEQ ID NO: 2), a single-stranded oligonucleotide having an RNA polymerase promoter sequence A second primer (having a sequence complementary to the sequence of the thermostable hemolytic poison gene) (SEQ ID NO: 3) complementary to was synthesized. The specific method was carried out on a 0.2M scale according to the ABI company manual. Deprotection of various oligonucleotides was carried out with ammonia water at 55 ° C overnight. Purification was carried out by FPLC manufactured by Pharmacia on a reverse phase column.
【0023】(腸炎ビブリオからのゲノムの調製)腸炎
ビブリオの菌株を 3% NaClを含むブレインハートインフ
ュージョン培地(Brain Heart Infusion Agar)に接種し
て、37℃で一晩培養した。成育したコロニーをそれぞれ
1.5mlのエッペンドルフチューブにかきとり、希釈用緩
衝液(0.1MNaH2PO4, pH 7.0) 300μlに懸濁した。さ
らにここへプロテイナーゼK(ナカライテスク社) 0.6
mg、溶菌液(8M尿素、0.25%ドデシル硫酸ナトリウム、
0.25%ラウリルサルコシンナトリウム、50mM EDTA, pH
7.6) 600μlを加えて撹拌し、60℃で30分間インキュベ
ートした。得られた溶解液をフェノールで2回、クロロ
ホルムで1回抽出後、エタノール沈澱し、核酸を得た。(Preparation of Genome from Vibrio parahaemolyticus) The strain of Vibrio parahaemolyticus was inoculated into Brain Heart Infusion Agar containing 3% NaCl and cultured at 37 ° C. overnight. Each grown colony
It was scraped into a 1.5 ml Eppendorf tube and suspended in 300 μl of a dilution buffer (0.1 M NaH 2 PO 4 , pH 7.0). Further to this Proteinase K (Nacalai Tesque) 0.6
mg, lysate (8M urea, 0.25% sodium dodecyl sulfate,
0.25% sodium lauryl sarcosine, 50 mM EDTA, pH
7.6) 600 μl was added, stirred and incubated at 60 ° C. for 30 minutes. The resulting solution was extracted twice with phenol and once with chloroform and then ethanol precipitated to obtain a nucleic acid.
【0024】(検出用プローブの調製) (1)リンカーアームを有する腸炎ビブリオ用オリゴヌ
クレオチドの合成 ABI社DNAシンセサイザー392 型を用いて、ホスホ
アミダイド法にて、配列表に示される配列、すなわち検
出用プローブ(配列番号4)を合成した。この際、特表
昭60-500717 号公報に記載された合成法により、デオキ
シウリジンから化学合成した 5位にリンカーアームを有
するウリジンを上記オリゴヌクレオチドに導入した。こ
のウリジンはオリゴヌクレオチド内の任意のTと置換し
うるが、この実施例においては5'末端のTを置換した。
合成されたリンカーオリゴヌクレオチドはアンモニア水
で50℃、一夜脱保護処理した後、ファルマシア社製FPLC
で陰イオン交換カラムを用いて精製した。(Preparation of Probe for Detection) (1) Synthesis of Oligonucleotide for Vibrio parahaemolyticus Having a Linker Arm Using a DNA Synthesizer 392 from ABI, the sequence shown in the sequence listing by the phosphoramidide method, that is, the probe for detection (SEQ ID NO: 4) was synthesized. At this time, uridine having a linker arm at the 5-position, which was chemically synthesized from deoxyuridine, was introduced into the above-mentioned oligonucleotide by the synthetic method described in JP-A-60-500717. This uridine can replace any T in the oligonucleotide, but in this example the 5'end T was replaced.
The synthesized linker oligonucleotide was deprotected with ammonia water at 50 ° C overnight, and then FPLC manufactured by Pharmacia
It was purified by using an anion exchange column.
【0025】(2)リンカーオリゴヌクレオチドのアル
カリホスファターゼによる標識化 上記リンカーオリゴヌクレオチドにそのリンカーアーム
を介して、アルカリホシファターゼを文献(Ncleic Acid
s Research, vol.14, p.6114, 1986) に従って結合し
た。リンカーオリゴヌクレオチド1.5 A260を0.2M NaHCO
3 12.5μl に溶解し、ここへ10mg/ml スベリン酸スクシ
ニミジル(DSS)25 μlを加えて、室温で2分間反応させ
た。反応液を1mM CH3COONa (pH5.0) で平衡化したSeph
adex G-25 カラム(1cmφ×30cm) でゲル濾過して過剰の
DSS を除去した。末端のアミノ基が活性化されたリンカ
ーオリゴヌクレオチドを、さらにモル比で2倍量のアル
カリホスファターゼ (100mM NaHCO3, 3M HClに溶解した
もの)と室温で16時間反応させることによりアルカリホ
スファターゼ標識プローブを得た。得られた標識プロー
ブはファルマシア製FPLCで陰イオン交換カラムを用いて
精製した。標識プローブを含む画分を集め、セントリコ
ン30K(アミコン社) を用いて限外濾過法により濃縮し
た。(2) Labeling of Linker Oligonucleotide with Alkaline Phosphatase Alkaline phosphatase was added to the above linker oligonucleotide via its linker arm (Ncleic Acid).
s Research, vol.14, p.6114, 1986). Linker oligonucleotide 1.5 A 260 with 0.2 M NaHCO
3 It was dissolved in 12.5 μl, and 25 μl of 10 mg / ml succinimidyl suberate (DSS) was added thereto and reacted at room temperature for 2 minutes. Seph equilibrated with 1 mM CH 3 COONa (pH 5.0)
Excess gel filtration with an adex G-25 column (1 cmφ × 30 cm)
The DSS was removed. An alkaline phosphatase-labeled probe was prepared by reacting a linker oligonucleotide in which the terminal amino group was activated with a double molar amount of alkaline phosphatase (dissolved in 100 mM NaHCO 3 , 3M HCl) at room temperature for 16 hours. Obtained. The obtained labeled probe was purified by Pharmacia FPLC using an anion exchange column. Fractions containing the labeled probe were collected and concentrated by an ultrafiltration method using Centricon 30K (Amicon).
【0026】(RNAポリメラーゼのプロモーター配列
をもつ一本鎖オリゴヌクレオチドの合成)腸炎ビブリオ
のゲノム1ngを緩衝液(50 mM Tris-HCl,pH8.3, 6mM MgC
l2, 40 mM KCl )に懸濁し、1mMデオキシリボヌクレオ
チド(Pharmacia)およびプライマー1、2と混合し、3分
間95℃で加熱後、室温になるまで放置した。PHI91 RN
Aポリメラーゼを4単位添加し、30℃で1時間保温し反
応を行った。(Synthesis of Single-Stranded Oligonucleotide Having RNA Polymerase Promoter Sequence) 1 ng of Vibrio parahaemolyticus genome was buffered (50 mM Tris-HCl, pH 8.3, 6 mM MgC
was suspended in l 2, 40 mM KCl), was mixed with 1mM deoxyribonucleotides (Pharmacia) and primer 2, after heating for 3 minutes 95 ° C., and allowed to come to room temperature. PHI91 RN
4 units of A polymerase was added, and the reaction was carried out by keeping the temperature at 30 ° C. for 1 hour.
【0027】(検出)上記反応液にプライマー3(配列
番号3)、10 mM DTT 、40ユニットのRNA依存性DN
Aポリメラーゼ (AMV 逆転写酵素)(東洋紡)0.4 ユニッ
トのリボヌクレアーゼ(RNaseH)(Pharmacia) 、20ユニッ
トのT7RNAポリメラーゼ(Stratagene)を添加し42℃
で3時間反応させた。反応液1μlをナイロン膜に滴下
後、アルカリ性条件下で核酸を固定した。この膜を中和
後、ハイブリダイゼーションバックに移し、上記アルカ
リフォスファターゼ標識核酸プローブ(配列番号4)を
含むハイブリダイゼーション・バッファー(5×SSC, 0.5
% ウシ血清アルブミン、0.5%ポリビニールピロリドン、
1%ドデシル硫酸ナトリウム) を加えて、50℃で15分間ハ
イブリダイゼーションを行った。ナイロン膜をポリバッ
クから取り出し、洗浄液1(1×SSC, 1% ドデシル硫酸ナ
トリウム) で50℃、10分間振盪洗浄した。さらに洗浄液
2 (1×SSC)で室温下10分間振盪洗浄した。膜を新しいハ
イブリダイゼーションバックに移し、基質液(0.1M Tris
-HCl, 0.1M NaCl, 0.1M MgCl2, 0.3mg/ml ニトロブルー
テトラゾリウム、0.3mg/mlブロムクロロフェリールホス
フェート pH7.5) を入れ、シール後、37℃で30分間イン
キュベートした。(Detection) Primer 3 (SEQ ID NO: 3), 10 mM DTT, 40 units of RNA-dependent DN were added to the above reaction solution.
A polymerase (AMV reverse transcriptase) (Toyobo) 0.4 unit of ribonuclease (RNaseH) (Pharmacia), 20 units of T7 RNA polymerase (Stratagene) were added, and the temperature was 42 ° C.
And reacted for 3 hours. After dropping 1 μl of the reaction solution onto a nylon membrane, the nucleic acid was immobilized under alkaline conditions. After neutralizing this membrane, it was transferred to a hybridization bag, and the hybridization buffer (5 × SSC, 0.5 × 0.5) containing the above-mentioned alkaline phosphatase-labeled nucleic acid probe (SEQ ID NO: 4) was used.
% Bovine serum albumin, 0.5% polyvinylpyrrolidone,
1% sodium dodecyl sulfate) was added, and hybridization was performed at 50 ° C for 15 minutes. The nylon membrane was taken out from the polybag and washed with Washing liquid 1 (1 × SSC, 1% sodium dodecyl sulfate) at 50 ° C. for 10 minutes with shaking. Further cleaning liquid
2 (1 × SSC) was washed by shaking at room temperature for 10 minutes. Transfer the membrane to a new hybridization bag and add substrate solution (0.1M Tris
-HCl, 0.1 M NaCl, 0.1 M MgCl 2 , 0.3 mg / ml nitroblue tetrazolium, 0.3 mg / ml bromochloroferryl phosphate pH 7.5) was added, and after sealing, the mixture was incubated at 37 ° C for 30 minutes.
【0028】(結果)生成物はプライマー1、2 (配列
番号 1、2)を同時に用いたときのアルカリホスファター
ゼにより生じる紫色色素のスポットが検出できた。(Results) In the product, a spot of a purple dye generated by alkaline phosphatase when primers 1 and 2 (SEQ ID NOs: 1 and 2) were used simultaneously could be detected.
【0029】図1は本発明のRNAポリメラーゼのプロ
モーター配列をもつ1本鎖ヌクレオチドを製造する全体
図を示す。図2は本発明により得られたRNAポリメラ
ーゼのプロモーター配列をもつ1本鎖ヌクレオチドを使
用する特定核酸配列の増幅方法を示す。図3は実施例1
のハイブリダイゼーションの結果を示す。図中、スポッ
ト1〜4はプライマー(配列番号1,2)存在下および
非存在下における実施結果を示す。スポット5はプライ
マー(配列番号1、2)存在下で特定核酸配列非存在化
におけるコントロールを示す。FIG. 1 shows an overall diagram for producing a single-stranded nucleotide having a promoter sequence of the RNA polymerase of the present invention. FIG. 2 shows a method for amplifying a specific nucleic acid sequence using a single-stranded nucleotide having an RNA polymerase promoter sequence obtained according to the present invention. FIG. 3 shows the first embodiment.
The result of the hybridization of is shown. In the figure, spots 1 to 4 show the results of the execution in the presence and absence of the primers (SEQ ID NOS: 1 and 2). Spot 5 represents a control in the absence of the specific nucleic acid sequence in the presence of the primers (SEQ ID NOS: 1 and 2).
【0030】[0030]
配列番号:1 配列の長さ:40 配列の型:核酸 鎖の数:両形態 トポロジー:直鎖状 配列の種類:他の核酸 合成DNA 配列の特徴 存在位置:1..20 特徴を決定した方法:S 他の特徴:T7転写開始配列と、耐熱性溶血毒遺伝子に相
同的な配列を有する。 配列:AATACGACTC ACTATAGCCCC GGTTCTGATG AGATATTGTT 40SEQ ID NO: 1 Sequence length: 40 Sequence type: Nucleic acid Number of strands: Both forms Topology: Linear Sequence type: Other nucleic acid Synthetic DNA Sequence features Location: 1..20 Method for determining features : S Other features: It has a T7 transcription initiation sequence and a sequence homologous to the thermostable hemolytic toxin gene. Sequence: AATACGACTC ACTATAGCCCC GGTTCTGATG AGATATTGTT 40
【0031】配列番号:2 配列の長さ:20 配列の型:核酸 鎖の数:両形態 トポロジー:直鎖状 配列の種類:他の核酸 合成DNA 配列の特徴 存在位置:1..20 特徴を決定した方法:S 他の特徴:耐熱性溶血毒遺伝子の配列に相同的な配列を
有する。 配列:GCTGCATTC AAAACATCTGC 20 SEQ ID NO: 2 Sequence length: 20 Sequence type: Nucleic acid Number of strands: Both forms Topology: Linear Sequence type: Other nucleic acid Synthetic DNA Sequence features Location: 1..20 Features Determined method: S Other characteristics: Having a sequence homologous to the sequence of thermostable hemolytic toxin gene. Sequence: GCTGCATTC AAAACATCTGC 20
【0032】配列番号:3 配列の長さ:26 配列の型:核酸 鎖の数:両形態 トポロジー:直鎖状 配列の種類:他の核酸 合成DNA 配列の特徴 存在位置:1..20 特徴を決定した方法:S 他の特徴:耐熱性溶血毒遺伝子の配列に相補的な配列を
有する。 配列:ATTTTACGAA CACAGCAGAA TGACCG 26 SEQ ID NO: 3 Sequence length: 26 Sequence type: Nucleic acid Number of strands: Both forms Topology: Linear Sequence type: Other nucleic acid Synthetic DNA Sequence features Location: 1..20 Features Determined method: S Other characteristics: having a sequence complementary to the sequence of thermostable hemolytic toxin gene. Sequence: ATTTTACGAA CACAGCAGAA TGACCG 26
【0033】配列番号:4 配列の長さ:25 配列の型:核酸 鎖の数:両形態 トポロジー:直鎖状 配列の種類:他の核酸 合成DNA 配列の特徴 存在位置:1..20 特徴を決定した方法:S 他の特徴:耐熱性溶血毒遺伝子の配列を有する。 配列:TCAGGTACTA AATGGTTGAC ATCCT 25SEQ ID NO: 4 Sequence length: 25 Sequence type: Nucleic acid Number of strands: Both forms Topology: Linear Sequence type: Other nucleic acid Synthetic DNA Sequence features Location: 1..20 Determined method: S Other characteristics: having the sequence of thermostable hemolytic toxin gene. Sequence: TCAGGTACTA AATGGTTGAC ATCCT 25
【図1】本発明のRNAポリメラーゼのプロモーター配
列をもつ1本鎖ヌクレオチドを製造する工程aから工程
cを示す。FIG. 1 shows steps a to c for producing a single-stranded nucleotide having a promoter sequence of the RNA polymerase of the present invention.
【図2】本発明のRNAポリメラーゼのプロモーター配
列をもつ1本鎖ヌクレオチドを使用する特定核酸配列の
増幅法を示す。FIG. 2 shows a method for amplifying a specific nucleic acid sequence using a single-stranded nucleotide having an RNA polymerase promoter sequence of the present invention.
【図3】実施例1のハイブリダイゼーションの結果を示
す。FIG. 3 shows the result of hybridization in Example 1.
Claims (4)
ポリメラーゼのプロモーター配列をもつ1本鎖オリゴヌ
クレオチドを製造する方法。 (a)特定核酸配列に、剥離用プライマーおよびRNA
ポリメラーゼのプロモーター配列をもつ第1プライマー
をハイブリダイズさせる。(ここで剥離用プライマーお
よびRNAポリメラーゼのプロモーター配列をもつ第1
プライマーは特定核酸配列の各相補的配列に結合でき、
その位置関係は剥離用プライマーの特定核酸配列の相補
的配列がRNAポリメラーゼのプロモーター配列をもつ
第1プライマーの特定核酸配列の相補的配列の3’側に
存在する。) (b)次いでヘリカーゼ様活性を有するDNAポリメラ
ーゼを用いて、RNAポリメラーゼのプロモーター配列
をもつ第1プライマーからの伸長反応を行う。 (c)さらに剥離用プライマーからの伸長反応に伴い、
特定核酸配列からRNAポリメラーゼのプロモーター配
列をもつ第1プライマーと該第1プライマーからの伸長
物で形成されるRNAポリメラーゼのプロモーター配列
をもつ1本鎖オリゴヌクレオチドを分離する。1. RNA comprising the following steps:
A method for producing a single-stranded oligonucleotide having a polymerase promoter sequence. (A) A primer for peeling and RNA for a specific nucleic acid sequence
A first primer having a polymerase promoter sequence is hybridized. (Here, a first primer having a peeling primer and a promoter sequence of RNA polymerase
A primer can bind to each complementary sequence of a particular nucleic acid sequence,
The positional relationship is such that the complementary sequence of the specific nucleic acid sequence of the peeling primer is present 3'to the complementary sequence of the specific nucleic acid sequence of the first primer having the promoter sequence of RNA polymerase. (B) Then, using a DNA polymerase having helicase-like activity, an extension reaction from the first primer having a promoter sequence of RNA polymerase is performed. (C) Furthermore, with the extension reaction from the peeling primer,
A single-stranded oligonucleotide having an RNA polymerase promoter sequence formed by a first primer having an RNA polymerase promoter sequence and an extension product from the first primer is separated from the specific nucleic acid sequence.
(c)が同時に行われることを特徴とするRNAポリメ
ラーゼのプロモーター配列をもつ1本鎖オリゴヌクレオ
チドを製造する方法。2. A method for producing a single-stranded oligonucleotide having a promoter sequence of RNA polymerase, wherein step (b) and step (c) in claim 1 are performed simultaneously.
るRNAポリメラーゼのプロモーター配列をもつ1本鎖
オリゴヌクレオチドと特定核酸配列との二重鎖領域が、
ヘリカーゼ様活性をもつDNAポリメラーゼの作用によ
り、剥離用プライマーからの伸長反応にともない巻戻さ
れ、RNAポリメラーゼのプロモーター配列をもつ1本
鎖オリゴヌクレオチドが特定核酸配列から分離されるこ
とを特徴とするRNAポリメラーゼのプロモーター配列
をもつ1本鎖オリゴヌクレオチドを製造する方法。3. A double-stranded region of a single-stranded oligonucleotide having a promoter sequence of RNA polymerase formed in step (c) of claim 1 and a specific nucleic acid sequence,
RNA characterized by being unwound by the action of a DNA polymerase having a helicase-like activity in association with an extension reaction from a stripping primer, and a single-stranded oligonucleotide having a promoter sequence of RNA polymerase is separated from a specific nucleic acid sequence. A method for producing a single-stranded oligonucleotide having a polymerase promoter sequence.
ポリメラーゼのプロモーター配列をもつ1本鎖オリゴヌ
クレオチドを用いた特定核酸配列の増幅法。 (A)請求項1において製造したRNAポリメラーゼの
プロモーター配列をもつ1本鎖オリゴヌクレオチドに第
2プライマーをハイブリダイズさせる。 (B)次いでDNAポリメラーゼを用いて伸長反応を行
い、二重鎖DNAを合成した後、 (C)二重鎖DNAにRNAポリメラーゼを反応させて
一重鎖RNAを複数合成する。 (D)一重鎖RNAを鋳型として、第2プライマーをハ
イブリダイズさせる。 (E)次いでRNA依存性DNAポリメラーゼを用い
て、RNA−DNAハイブリッドを形成させる。 (F)RNA−DNAハイブリッドのRNA部分を分解
し、一本鎖DNAを得る。 (G)得られた一本鎖DNAにRNAポリメラーゼのプ
ロモーター配列をもつ第1プライマーをハイブリダイズ
させ、伸長反応を行い、二重鎖DNAを合成する。 (H)さらに工程(C)から(G)を繰り返して特定核
酸配列を増幅する。4. RNA comprising the following steps:
A method for amplifying a specific nucleic acid sequence using a single-stranded oligonucleotide having a polymerase promoter sequence. (A) The second primer is hybridized with the single-stranded oligonucleotide having the promoter sequence of RNA polymerase produced in claim 1. (B) Next, an extension reaction is performed using a DNA polymerase to synthesize double-stranded DNA, and then (C) the double-stranded DNA is reacted with RNA polymerase to synthesize a plurality of single-stranded RNAs. (D) The second primer is hybridized with the single-stranded RNA as a template. (E) Next, an RNA-DNA hybrid is formed using an RNA-dependent DNA polymerase. (F) The RNA portion of the RNA-DNA hybrid is decomposed to obtain single-stranded DNA. (G) The obtained single-stranded DNA is hybridized with a first primer having an RNA polymerase promoter sequence, and an extension reaction is performed to synthesize a double-stranded DNA. (H) Further, steps (C) to (G) are repeated to amplify the specific nucleic acid sequence.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP14360893A JPH0716094A (en) | 1993-06-15 | 1993-06-15 | Production of single-stranded oligonucleotide having promoter sequence of rna polymerase |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP14360893A JPH0716094A (en) | 1993-06-15 | 1993-06-15 | Production of single-stranded oligonucleotide having promoter sequence of rna polymerase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH0716094A true JPH0716094A (en) | 1995-01-20 |
Family
ID=15342692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP14360893A Pending JPH0716094A (en) | 1993-06-15 | 1993-06-15 | Production of single-stranded oligonucleotide having promoter sequence of rna polymerase |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0716094A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1539979A4 (en) * | 2002-09-20 | 2006-01-11 | New England Biolabs Inc | Helicase dependent amplification of nucleic acids |
| US7662594B2 (en) | 2002-09-20 | 2010-02-16 | New England Biolabs, Inc. | Helicase-dependent amplification of RNA |
| US9416387B2 (en) | 2013-03-15 | 2016-08-16 | Theranos, Inc. | Nucleic acid amplification |
| US9551027B2 (en) | 2013-03-15 | 2017-01-24 | Theranos, Inc. | Nucleic acid amplification |
| US9916428B2 (en) | 2013-09-06 | 2018-03-13 | Theranos Ip Company, Llc | Systems and methods for detecting infectious diseases |
| US10450595B2 (en) | 2013-03-15 | 2019-10-22 | Theranos Ip Company, Llc | Nucleic acid amplification |
| US11254960B2 (en) | 2013-03-15 | 2022-02-22 | Labrador Diagnostics Llc | Nucleic acid amplification |
-
1993
- 1993-06-15 JP JP14360893A patent/JPH0716094A/en active Pending
Cited By (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1539979A4 (en) * | 2002-09-20 | 2006-01-11 | New England Biolabs Inc | Helicase dependent amplification of nucleic acids |
| US7282328B2 (en) | 2002-09-20 | 2007-10-16 | New England Biolabs, Inc. | Helicase dependent amplification of nucleic acids |
| US7662594B2 (en) | 2002-09-20 | 2010-02-16 | New England Biolabs, Inc. | Helicase-dependent amplification of RNA |
| US7829284B2 (en) | 2002-09-20 | 2010-11-09 | New England Biolabs, Inc. | Helicase-dependent amplification of nucleic acids |
| US10017809B2 (en) | 2013-03-15 | 2018-07-10 | Theranos Ip Company, Llc | Nucleic acid amplification |
| US9551027B2 (en) | 2013-03-15 | 2017-01-24 | Theranos, Inc. | Nucleic acid amplification |
| US9725760B2 (en) | 2013-03-15 | 2017-08-08 | Theranos, Inc. | Nucleic acid amplification |
| US9416387B2 (en) | 2013-03-15 | 2016-08-16 | Theranos, Inc. | Nucleic acid amplification |
| US10131939B2 (en) | 2013-03-15 | 2018-11-20 | Theranos Ip Company, Llc | Nucleic acid amplification |
| US10450595B2 (en) | 2013-03-15 | 2019-10-22 | Theranos Ip Company, Llc | Nucleic acid amplification |
| US10745745B2 (en) | 2013-03-15 | 2020-08-18 | Labrador Diagnostics Llc | Nucleic acid amplification |
| US11254960B2 (en) | 2013-03-15 | 2022-02-22 | Labrador Diagnostics Llc | Nucleic acid amplification |
| US11603558B2 (en) | 2013-03-15 | 2023-03-14 | Labrador Diagnostics Llc | Nucleic acid amplification |
| US11649487B2 (en) | 2013-03-15 | 2023-05-16 | Labrador Diagnostics Llc | Nucleic acid amplification |
| US9916428B2 (en) | 2013-09-06 | 2018-03-13 | Theranos Ip Company, Llc | Systems and methods for detecting infectious diseases |
| US10283217B2 (en) | 2013-09-06 | 2019-05-07 | Theranos Ip Company, Llc | Systems and methods for detecting infectious diseases |
| US10522245B2 (en) | 2013-09-06 | 2019-12-31 | Theranos Ip Company, Llc | Systems and methods for detecting infectious diseases |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6063604A (en) | Target nucleic acid sequence amplification | |
| JP2648802B2 (en) | Enhanced nucleic acid amplification method | |
| EP0682120B1 (en) | Selective amplification of target polynucleotide sequences | |
| US5215899A (en) | Nucleic acid amplification employing ligatable hairpin probe and transcription | |
| JP3080178B2 (en) | Method for amplifying nucleic acid sequence and reagent kit therefor | |
| US6001558A (en) | Amplification and detection of HIV-1 and/or HIV 2 | |
| KR100231383B1 (en) | Nucleic acid amplification with dna-dependent rna polymerase activity of rna replicases | |
| JP3514630B2 (en) | Amplification and detection of nucleic acid sequences | |
| JP3360977B2 (en) | Highly sensitive nucleic acid detection method | |
| US5688669A (en) | Methods for nucleic acid detection, sequencing, and cloning using exonuclease | |
| EP0427074A2 (en) | Nucleic acid amplification employing transcribable hairpin probe | |
| US5744306A (en) | Methods for nucleic acid detection, sequencing, and cloning using exonuclease | |
| KR20010012175A (en) | Two-step hybridization and capture of a polynucleotide | |
| AU2002366098A1 (en) | Multiplex pcr | |
| US6100024A (en) | Methods and compositions for nucleic acid detection by target extension and probe amplification | |
| US5853981A (en) | Oligonucleotides, methods and kits for amplifying and detecting a nucleic acid of cytomegalovirus (CMV) using nucleic acid sequence β2.7 | |
| US5952201A (en) | Method of preparing oligonucleotide probes or primers, vector therefor and use thereof | |
| US5925518A (en) | Nucleic acid primers for amplification of a mycobacteria RNA template | |
| JP4553412B2 (en) | Primers and probes for amplification, detection and typing of Mycoplasma pneumoniae | |
| US5972607A (en) | Methods for nucleic acid amplification with thermostable ribonuclease H | |
| JPH04229200A (en) | Improved lcr process | |
| JPH05146299A (en) | Method for amplifying nucleic acid sequence and reagent kit therefor | |
| JPWO2009044773A1 (en) | Legionella genus rRNA amplification primer, detection method and detection kit | |
| CA2150986C (en) | Oligonucleotide primers and probes for detection of bacteria | |
| JPH1066589A (en) | Strand displacement amplification with boronated nucleotide |